Onconome, Inc

Onconome Inc. has developed a blood test to detect colon cancer with greater than 93% sensitivity and 82% specificity. Onconome Inc. has developed a blood-based test which, in three separate studies involving nearly 1,000 patients, has demonstrated t...

Onconome Inc. has developed a blood test to detect colon cancer with greater than 93% sensitivity and 82% specificity. Onconome Inc. has developed a blood-based test which, in three separate studies involving nearly 1,000 patients, has demonstrated the ability to accurately determine an individual's probability of having colorectal cancer (CRC). The test, ONC107, is highly sensitive to CRC (93.75%) and also highly specific to CRC (82.89%). As importantly, the test yields a negative predictive value (NPV) of 99.9775%, meaning that a negative test result establishes with near certainty that an individual does not have CRC. Additional, prospective studies involving another 1,000 patients are underway to validate these encouraging, clinically significant results and to further establish ONC107's ability to detect dangerous pre-cancerous adenomatous polyps in the colon.